MedTrace Logo

Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab

NCT02008890 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 237

Last updated 2019-01-04

Study results available
· View outcomes & findings →

Summary

A one year study assessing the efficacy and safety of secukinumab compared with placebo in adult patients with moderate to severe palmoplantar pustular psoriasis - amended with an optional extension treatment period of up to a total of 148 weeks

Conditions

  • Palmoplantar Pustular Psoriasis

Interventions

BIOLOGICAL

Secukinumab 300mg

Secukinumab was used as 150 mg pre-filled syringes (PFS) in a double-blinded fashion. Secukinumab 300 mg s.c. (two PFS injections of the 150 mg dose) self-administered

BIOLOGICAL

Secukinumab 150mg

secukinumab 150 mg s.c. (one PFS injection of the 150 mg dose + one PFS injection of placebo) self-administered

BIOLOGICAL

Placebo

secukinumab placebo s.c. (two PFS injections of placebo) self-administered

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-26
Primary Completion
2014-11-24
Completion
2017-05-31

Countries

  • Austria
  • Belgium
  • France
  • Germany
  • Italy
  • Poland
  • Russia
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02008890 on ClinicalTrials.gov